JNCCN 360 – Bladder – Durvalumab Indication Withdrawn in Advanced Bladder Cancer in the United States

By: JNCCN 360 Staff Posted: Thursday, February 25, 2021 On February 22, AstraZeneca announced the voluntary withdrawal of the PD-L1 inhibitor durvalumab (Imfinzi) indication in the United States for previously treated adults with locally advanced or metastatic bladder cancer. This decision was made in…

Read the full article here

Source: jnccn360.org
Categories: Hem/Onc News and Journals, Latest Headlines
Tags: , , ,
Tweets with this article
Journal of the @NCCN
#durvalumab indication withdrawn in advanced #bladdercancer in the United States: https://t.co/O5DtFQoS6Z #blcsm #JNCCN360 https://t.co/E9QcyTXWeF

Related Articles